The Inspire therapy represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. The company markets its implantable device primarily through a network of sleep centers and hospitals with a business model that combines device sales with a supportive service infrastructure, with revenue streams fueled by initial device sales plus ongoing follow-ups and software updates.
Cyborg Score Rationale
Inspire Medical reported fourth quarter revenue of $269 million (up 12%) and full year revenue of $912 million (up 14%), driven by growth at existing and new centers. The company maintains market leadership in sleep apnea neurostimulation with FDA-approved technology and strong demand. However, recent securities class action lawsuits and regulatory challenges like prior authorization programs may present headwinds.
Top Insights
Full year 2025 revenue reached $912 million with 14% growth driven by expansion at existing and new centers
Over 90% of centers now implanting Inspire V, the newest generation device
WISeR Medicare prior authorization program impacting procedures in six states in Q1 2026
Company originated as spinoff from Medtronic in 2007, providing strong pedigree and technology foundation
Named Competitors
CPAP and BiPAP Machines — Traditional air pressure devices for sleep apnea
Oral Appliances — Mandibular advancement devices for OSA treatment
Surgical treatments — Surgical interventions for airway obstruction
Recent Developments
(December 2025) Multiple securities class action lawsuits filed following stock decline
(2025) FDA approval for Inspire IV with 3 Tesla MRI compatibility
(2025) Full year revenue of $912M with 14% YoY growth
(Early 2026) WISeR Medicare prior authorization program implementation impacting procedures
Open the full interactive Inspire Medical Systems, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.